HUE033352T2 - Biciklusos vegyületek mint alfa4-béta2 nikotinos acetilkolin receptor ligandumok - Google Patents
Biciklusos vegyületek mint alfa4-béta2 nikotinos acetilkolin receptor ligandumok Download PDFInfo
- Publication number
- HUE033352T2 HUE033352T2 HUE09818648A HUE09818648A HUE033352T2 HU E033352 T2 HUE033352 T2 HU E033352T2 HU E09818648 A HUE09818648 A HU E09818648A HU E09818648 A HUE09818648 A HU E09818648A HU E033352 T2 HUE033352 T2 HU E033352T2
- Authority
- HU
- Hungary
- Prior art keywords
- azabicyclo
- esia
- compound
- yloxymethyl
- hexane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (4)
- «««OS VEGYÜLETEK: M!NT ALF&4-BÉTA2 NIKOT1NOS ACETIí AiOLm RECEPTOR 1 MiANDEMOS : :lgÉí|:piOfe; 1 Y&gvkuík t kbw'ík«V{> >Γ> aPalaaoN aopiousU* és aznk $ztereobo«K*rki vagv jjyógyá^zaiHag eltogadható soi; aiHíi R {dentóse anKxopofí vagv heseraan; esopork R, K'SewoM' hub''-cí.‘uauw^ dUk<\op'>5s vae> >aU\xdksK'M>pao'; R c i'R’^c hidu>^0-»xju>sa, aíku csopa<k dW\* ιν'^Ά, 0íU<»<<!kil-^.."'iOíi< aíke>ukd aikd'cxoport, oVU>alkw¡>eso|jort. smi-csopork keíeKKíUd- ci^per? vagy heiemdkUkaíksl-esopfHl; R\ jdentése iddrogénatom. hsdroxi-eaopori, haiogénatum* ko-&soports naro~caopott, íunsd-csopori, amm-esoporp karboxii-csoport, dkii-eva¡*.ak a*K'*v vp'pon, eAuíalkd-c.soporr. esk)uafkd"»skü--esopork cikkwikoxi-csopoít, kdogeswükd es* sport, hanger-a->d->s\< o?opo5k heu ^i-vskiü csopusi \ag\ ίκΚ'ίοοΑΗ-ΰΐΜί-ονίρ^ίΐ, >jn" artóke 1 -tos 4-sg seneo; ,as" erléks,' i -tól Asg foned »p" atéke 0-t<d 2-ig sened, a/,?ai a idfétdlek hogy a w^úíwmmm a UnctMVo p'd kcpioiu νι^'Ή'1 ^ PtVí:(A). Jk Aggfklet a® h igtnypotH s¿ennk amdy a küveíke/ikltes 41 k> esoporíbof v.kp váii§?|.Vá< d-(pifHjin'd'd' ox i-meb i }-2-azabtcíklo|3.1.Ofhexáo-d* akssx>& iond; 2-ítjetn->-{piridínAvH-,».KMi«íiil>-:-ii?abicikIof3.i.01ht*xáíi; 3··; a ·medbpuidkK'-P;· j~oxs -nuríd í-^axabicikiot 4-1 .Ofiiexáñ-dshídrokloríd; * L abn puídrs-' iPoxí n taP-J cvabk'ikM * 1 u;!v\dn'dih«1sv>kk>n*k * < ' Hoi-psnd e~* i nv' ¡s\al ' abk skk>[' $ Odk\ bh'dsok asa 4 A ü' os aukísa " t* om s'kt s C a\*Hu\ oA ' t',i N dsbkluAl > ^«SAk'í-p»tdií>>^-íi oxs-mc'dlid^akioskksfdJ.OdH'xan dshdrokk'fui, 1 ν' bíoíS-i p»»»o ' í \ <-v > \ í'p ? (e^alik\' 1 Ήϊννη» ^uar u ks3 ticos psssxbn- * U ''AwnHúi·N '>Uoj3 kihex sst km swk 3' bMluot · ptrsdts*· 3-i \ - o\o sne-tü p 2xaetUO» axabññUo|3.1,0}ist-NaO'ta*Mál:k * ! 3'kÍ0S'pslíCÜn < d ' \ ΊΠίΗί.Π-,'' sectil-2 x/ab'C*kkv ' i ^ííIvá sn; 2- ss)eük3-(2-msddpiskbsn3-skoxks$seidk2';sxabse8kM 3. i .OlhexáiK 2 - metil '3'{2-81)0851- psndtn-S di-oas -ose? íi s^mxabicskiol ?. i .OJhcssák ^ K O* Wli"i N i \ ss.'U 4 2 ¿i ' do ^ ' <t \n »' 3- t2-t1uor-pm8Hi)“5”ií'Oxkinefii)'-2-metií-2-a?.abicikkíf3i.L0}hexin: 3-(S-kibo psmtin-.il· skoxkroesif}' 2 msebk2--m:abicski<H3· í ,.0]hexásv. i f-»rom psnsho y-d-orn-oscnl)-4 mcul 3 xSxOíkK'sU 33 \ t s j h e χ a o ~4 s o ¡ d ío t- 1 os¡o' 3·-«2·ΓηοΡΐφίήί!ίϊ5·'3'8ΐ-οχ!-{·{ϊούΓ;<2'·3ΧδΙ'>ϊθϊΚ1ο|}.1<0!Ι'8οχ;ΐ!ρ 5-(2'a«?»biojklof3.LO|hex-3'iI-TOetoxi^n<li«-'2*karb<msavv3í?ud<· ."Wií-a'abioUo!* i k>lhc\ 3 sl-me-orn spsndm 3 kasívtsM\, ' v-ksíset^M'pisfdso 3 ú í'\-5no'u;-3-χ/λ!'<;cikk¡I3 i Olbevan; 3-{2-i-<í:opvo|X>\i-pmcíin--3-i!*nxi-n)eíil)>2-3£ab5dk!«|3.LO|hexán; s «3'íivnl 3 ^'sk^vilhílJ.kdlbex < d-sootoM'>p>s*Ji*s*2 k^bor·^ mnsd 5-{2-m#íll'*t-#í&bjdklo(3.l.0)hesK^bmetoxí)pindin-'2-ka?bonp-y-; ks 2'sooun kpsm.ksv5--Ü -ox s-rnedi Komiedl '2~a/ahsdkioj 3,1.0 jhexatr. 3"(2“Szopfopoxi'pkid5n--5^i!-Px{--n5e5Uk2-íi)eUl-2-axafeieikto(3>LÍÍ:]b3xÉk 5*f I -(2axabíelkíop. 1.0)hex>3-ii}-eíoxi|piñ<ün--.2--il·-aisímÍ 3-i2'psm>ikbss 1 -si-p?rsd< n -5- d - ox s~ ose? si k3-a/a-bie;ki o| 3.1 k|hcxs*ss; ρ {* i.2 mcfsi 2 oxd\cíMo|,4 I Ο^ν mKtoxs psudsss 2 n xtmitn 2- mv f s k3 4 2 - putos sdin- i -i k ps ddi ss- 5- i 1 -ox s- ¡neis k 2 svx & b ic i b !op. ΙόφΜ&η í .>( pirsdsss- 3- si -oxs-mdsi í-2-;wabidkksj4,1 Jkhepkd:. 3np snetb psndm 3-d-oM'STíosdo2-tl/aHuüojd 5 0}?u ptám M2«meHi-pmdin-3-if-oxkmeíi!V2-a*abfcík)0Í4JxO]hepuln: o ' do psísd'ii * ss ή m« ^ ' u/absesv x»{ - 1 k >< pnt' ¿-medí-3-(2 · metH~pir}diO'3»ü*fjíxkmob1)'2-aü;ahiclkio( 4. i .0 lheprá«| ki5-ki3s-psrkisn-3-si-oxs-míHÍIk2-sne?ík2'íw.sibk'skkvi4J.0]|Hpkm; P'i» SI * (<\!\V¡ "* ^ drtx*k<‘{ M k||'í,s<iJ 442-(5-21or- pirix i i ¡v- 3 -d - o x i )e til k 2- ssies i! - 2 - ax a hk i kioi 3 4.0 i he a ass; 3 (piridi η-3-ií - οχ i-stveii 0-2 -axabicskloH I .Olísepfxln-h kirok lorsd: 3- {5-klór-piíkilo-3-d-oxs-meiily^-axabitsklo|4. i Adhepsnn--hidt<>ktofid; .<&: íixok v/so!T<;m>merj£Í vagy gyógváHxatüssg eifogadható aói. 3» Vegyñíet a* I. igéssyponi vxetifiL ¿ssiiesy egy s/erveU«« sawa* x agy pgy sxervo 'sav'val alkoloH gydgyászuiüag ellUgadfvatd savaddíaés so h.smssijában ál! roíidoíkoxxksrc* alio! « n a'Dodosi \<s\ xS kxíxcfkc/O' bsPsnh'xdfoyiesoxsx ds^ds^hubnvo k koí'^.si, xaMsosiOxj^ vagy k-i\;dos'sav; é;> ;s ΧίΧΟχχχ *av si kdveíkexo: bosostyásikdsav, nsaieifsxa^ t mnsav, fsiixíxüx»' cliso i>á\ xísmxOxS'v %>tkoxxSX' bt>i/t»cvu. r ^i„siívc p-soiuoN «ik'nxas sooiJsixX£i¡ybosav vagy ¡'SüiVaiónsic.idfoíssav'.
- 4. EijAráx egy u?. \. sgdnypom sxe.dnsi i!) ákakioos kcpleiü vcgyükissek xx esoáHHasáoí: kjvéxe. hugy a? (3i) kcpíesü vcgyiliet blnil Isxás'vk; imÉy fijarás- migában Asgiaija k kovcrkeiíókes' (a) a Ipvpkead (í) llfslinos Mplsiü ¿ttgállM&P -a. MaáRtP$ (9) iltállnós Id ρ fe? a tlMf (dib v egydlstM;í $ l haga egy a Mvaikespib) a Π.0) ált&Maox fcéaléib eegyakt átalaféMsa a Mxefkesft d i ) ákafános kéglerü íMp vadeas: aegybfcaé lámele eegyüies. eéd&sog&ríjaaak as ellávelífása aMesa);le) a {1/1): Ikaláeoa képfeíü vegyLUes lakaMiása as t!) ékaiánox kbplesü vagyüleué, opemaál&áa ar(I> ibalasies kgpMü vegyllM ltafakáá% annak egy gyégyásyunüag diegadheP djuvá: aba! Id Ru Rj:, 1¾¾ es n es p jeleádse as 1, Igdaypontbaa aieghadrosdsak sserielk 5> /Bljérls egy as .), Igsaypaef asedad (I) ál.íaláam képMd vegyülepek as elMBfiadíá, :kivdm hogy ás iá.) kepis!)! vsgyulgt apea klsásda, abo! as a ikpvetkeso fi!) átedloes képkaü;(Í|.): : ame I v t-lJMl m&gáfeaa 1¾¾¾¾ a teVeitefttól (a) g kdvetkead: (8) akMáMá fcif%tlky«fyf!#f rfgglltaíása ¡a klveito# (9.) tialldos képküi h i tiras: i í -vegyü leliéb«9) bagy ágg a kPvaiMyiC10| ágsjánaa képhnü vegyyfeí legygablpyyvg::(b> a (ib) áltaianos kepíefM vegyükf: átatókitósa a [i,í¡ állaláaes képialu Pesia y#tet vsgykiettk (amsly yygyüfetvádbesopofijáñálv ay eMveiMsy tb?t|ál); alio! Ib Rs, 11¾ Es, m, a és p jglgpífee az lyIggnyponflMígffiaglíaMraáOíbE saebabo E E||ás'ás ay 5, igsswpopi sze#«g aboba: (10} gkalános klpMb vegyuioi a (i i:) al^aaos Mpfera vsgytbeOg sfeíVpyk vágy piñuorkavMk (ibfíacsr'-éaataavaalc) egy oldosxorbes? Idodoo áika(p):aylaáya| van iMfakftxk pildáol ogy oMésaorke», ameiy a kgv&ikMgk kdyül van válasviva: eíamik MmfekímfUé&í, joluo!, gbkaodíág lyópyjpaaük dtyOlkkk dlkidyynefga vagy azdk egy kgvarlke; ", amdx '„a'Jdxa< egx , , igc«xpen* */νηιαι \C£\ukk% km-xa Ιη>λ aa Λ11' epK'ii xegx.dot as».' xagx cí\' χ- sgfm\p*«u\,»p , ' s¿y»A'om $mte i ί vegyttl etet * kNogxa^ab kí-íítnu:^ a " «ρόχροΉΐ .v*eHnt, jiaI) x.***ahj*.x.» ^ - vs h'H* ku>' «o o<t'U lagonsfi .¾ vO'-cAe^k^o! ,iH" O'-opouM M-as/^a ^ U! κμ'ΡΚικΑ, ι<-\ΒΛ moerz agomstók é\ más aikotmos aceühmím recepirnok,
- 9. Gyógyác/au kéteínaér>y a 1. igátypont vagy a 8. igénypoitf szmnt. ameíy a kx>ve*ke?,6fc tn xvSÜeiU'VSKí. oa> hiNoua, karvA. por. vopoga»' taH^uk s " ' « ^ * j ' \ *"\ n *ep obi a «* io >», > χ'ίν ΐ! " iNs», a*vl „ ws , } .j '! iU» iN sj?> >.' do \ a' > yKv^v^v'ívW'n tóríéñci amigo lito, Ni (oogyus^ati kc$/iwjtn> -s Ά-ίδϊ <Mg igénypomok bárnwiyike szenni, eg> aUapctnek a ko<rclvν'Κ'χχ 'oitooo aikAnoso>\ra, amo)' a koxmke'<A kcvui xa» xala.Níí’x.i. hopo egv koamov roemoria?.»x.«· saagolur , lOgníoyf' mcmory assisisiei"). iujdaiom· vagv eihtek. il Vegyiskf :« L igé»ypmd sztnm, kiveve, hogy az sA> kdpleíü vegyükt «mes kizárva, xag> vxygusk't á 2 igoaxpos« xaya a " oaiopom \,>er,m gYoyAtN¿..»'i uaxoso ¿dkalomAVaa. Í2> Vcgyükn az L igénypont seriar, kivtvc. hogy a?. (A) kdpieiü vegydlei nirics Kizárva. vagy vegyüks a 2. igénypont vagy a 3. igdnvpom sraiti, beieg&égeknek a kttrd&fteR ibmioD aikalmazáani, amdyek «40? »ik toninos recepíorral kapesolaíoyak.
- 13, VegyUlet a¿ 1, igénypom sxeribftt, fcivévc, hogy a* (A) képlerü vcgytHel nines kixám. vgv >cgu¡Ut a 2 igsnvpom xa«x ai igenxpom ko/uí Kirmdvsk vennt, cg\ aHapotnak a k> sVi' ·>χ*Κ*« ν«Α\ν> ..akal»»» >ook amch i kuXYí^<ik \oaOi xa» vaí«»-ftxa 'kp^^vao ogy kogníuv mesoón;o'.avia' ómgohik «cognúive memory xlssoidor*'), íáglalooi vagy esmziv
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2838CH2009 | 2009-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE033352T2 true HUE033352T2 (hu) | 2017-11-28 |
Family
ID=42228992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09818648A HUE033352T2 (hu) | 2009-11-18 | 2009-12-31 | Biciklusos vegyületek mint alfa4-béta2 nikotinos acetilkolin receptor ligandumok |
Country Status (24)
Country | Link |
---|---|
US (1) | US8735423B2 (hu) |
EP (1) | EP2513085B1 (hu) |
JP (1) | JP5536227B2 (hu) |
KR (1) | KR101376145B1 (hu) |
CN (1) | CN102741239B (hu) |
CA (1) | CA2773409C (hu) |
CY (1) | CY1118361T1 (hu) |
DK (1) | DK2513085T3 (hu) |
EA (1) | EA020506B1 (hu) |
ES (1) | ES2601905T3 (hu) |
HK (1) | HK1175782A1 (hu) |
HR (1) | HRP20161461T1 (hu) |
HU (1) | HUE033352T2 (hu) |
IL (1) | IL219637A (hu) |
LT (1) | LT2513085T (hu) |
MX (1) | MX2012005637A (hu) |
NZ (1) | NZ600536A (hu) |
PL (1) | PL2513085T3 (hu) |
PT (1) | PT2513085T (hu) |
RS (1) | RS55469B1 (hu) |
SI (1) | SI2513085T1 (hu) |
SM (1) | SMT201600444B (hu) |
WO (1) | WO2011061751A1 (hu) |
ZA (1) | ZA201203522B (hu) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS54888B1 (sr) * | 2011-06-17 | 2016-10-31 | Lilly Co Eli | Derivati biciklo(3.1.0)heksan-2,6-dikarboksilne kiseline kao agonisti mglu2 receptora |
JP6103240B2 (ja) | 2013-11-18 | 2017-03-29 | トヨタ紡織株式会社 | ピッチ材料の調整方法及び調整装置 |
US10945771B2 (en) | 2017-06-09 | 2021-03-16 | Merck Sharp & Dohme Corp. | Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor |
AU2023207848A1 (en) | 2022-01-11 | 2024-07-04 | Suven Life Sciences Limited | Heteroalicyclic derivatives and their use in the treatment of cns disorders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4337341A (en) | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
AU7871498A (en) * | 1996-12-20 | 1998-07-17 | Novo Nordisk A/S | A method of treating hypercholesterolemia and related disorders |
AU781438B2 (en) * | 1999-06-30 | 2005-05-26 | Daiichi Pharmaceutical Co., Ltd. | VLA-4 inhibitor compounds |
EP1435955A2 (en) | 2001-05-05 | 2004-07-14 | SmithKline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
FR2889187B1 (fr) | 2005-07-28 | 2007-09-07 | Servier Lab | Nouveaux composes 1,1-pyridinyloxycyclopropanamines polysusbstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
TWI405763B (zh) | 2006-11-02 | 2013-08-21 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
-
2009
- 2009-12-31 US US13/499,998 patent/US8735423B2/en active Active
- 2009-12-31 NZ NZ600536A patent/NZ600536A/xx unknown
- 2009-12-31 CA CA2773409A patent/CA2773409C/en active Active
- 2009-12-31 CN CN200980162485.1A patent/CN102741239B/zh active Active
- 2009-12-31 PT PT98186489T patent/PT2513085T/pt unknown
- 2009-12-31 EP EP09818648.9A patent/EP2513085B1/en active Active
- 2009-12-31 JP JP2012539471A patent/JP5536227B2/ja active Active
- 2009-12-31 HU HUE09818648A patent/HUE033352T2/hu unknown
- 2009-12-31 DK DK09818648.9T patent/DK2513085T3/en active
- 2009-12-31 PL PL09818648T patent/PL2513085T3/pl unknown
- 2009-12-31 SI SI200931545A patent/SI2513085T1/sl unknown
- 2009-12-31 EA EA201290344A patent/EA020506B1/ru unknown
- 2009-12-31 ES ES09818648.9T patent/ES2601905T3/es active Active
- 2009-12-31 WO PCT/IN2009/000758 patent/WO2011061751A1/en active Application Filing
- 2009-12-31 RS RS20160961A patent/RS55469B1/sr unknown
- 2009-12-31 KR KR1020127008755A patent/KR101376145B1/ko active IP Right Grant
- 2009-12-31 LT LTEP09818648.9T patent/LT2513085T/lt unknown
- 2009-12-31 MX MX2012005637A patent/MX2012005637A/es active IP Right Grant
-
2012
- 2012-05-07 IL IL219637A patent/IL219637A/en active IP Right Grant
- 2012-05-15 ZA ZA2012/03522A patent/ZA201203522B/en unknown
-
2013
- 2013-03-13 HK HK13103118.6A patent/HK1175782A1/xx unknown
-
2016
- 2016-11-04 HR HRP20161461TT patent/HRP20161461T1/hr unknown
- 2016-11-07 CY CY20161101138T patent/CY1118361T1/el unknown
- 2016-12-06 SM SM201600444T patent/SMT201600444B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010337837B2 (en) | Alpha4beta2 neuronal nicotinic acetylcholine receptor ligands | |
DK2507225T3 (en) | L-DIHYDRO-2-OXOQUINOLIN COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | |
US11278530B2 (en) | Polycyclic amides as muscarinic M1 receptor positive allosteric modulators | |
HUE033352T2 (hu) | Biciklusos vegyületek mint alfa4-béta2 nikotinos acetilkolin receptor ligandumok | |
AU2009355487C1 (en) | Bicyclic compounds as alpha4beta2 nicotinic acetylcholine receptor ligands |